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INTRODUCTION
The Hatch-Waxman Act1 of 1984 regulates approval by the
Food and Drug Administration (“FDA”) of generic counterparts to
patented drugs. In a series of recent cases, large pharmaceutical
companies have been accused of exploiting Hatch-Waxman in violation of the antitrust laws.2 In essence, the allegations are concerned with the large pharmaceutical companies that have paid
manufacturers not to market inexpensive generic versions of patented drugs, thereby restraining trade and maintaining a monopoly.3
In the case of Biovail v. Hoechst Aktiengesellschaf, Inc., the
generic drug manufacturer, Biovail, sued Hoechst Aktiengesellschaf (“Hoechst”), a pharmaceutical company, for antitrust violations resulting from Biovail’s effort to gain approval from the FDA
to market a generic version of Cardizem, a heart drug patented by
Hoechst. 4 The claims are that Hoechst unfairly manipulated the
Hatch-Waxman Act to prevent Biovail from obtaining FDA approval for a generic counterpart to Cardizem.5
Even though the defendant Hoechst, may have intended to exclude the plaintiff, Biovail, as competitors, Hoechst will be substantially immune from antitrust liability under the NoerrPennington doctrine (“Noerr Immunity”), because Hoechst was
acting within its constitutionally protected rights. 6 The Noerr Immunity enjoyed by Hoechst is necessary to insure that the freecompetition goals of the antitrust laws do not destroy Hoechst’s
right to petition the government, as guaranteed by the First
Amendment.7
1. 21 U.S.C. § 355(j) (1994 & Supp. IV 1998).
2. See Anne Marie Squeo, FTC Investigates Drug Makers’ Patents, SUN-SENTINEL,
March 10, 1999, at 3D.
3. Id.
4. 49 F. Supp. 2d 750 (1999) (denying motion of FTC dismissal).
5. Id.
6. Eastern R.R. Conference v. Noerr Motor Freight, Inc, 365 U.S. 127, 145 (1961)
(holding that the antitrust laws do not prohibit people from associating together to petition a branch of the government, even if the desired action is anticompetative.)
7. U.S. CONST. amend. I. “Congress shall make no law respecting an establishment

RESEKFMT.DOC

2000]

9/29/2006 3:19 PM

BIOVAIL v. HOECHST AKTIENGELLSCHAF

573

Part I of this Comment discusses both the legal framework of
the Hatch-Waxman Act as well as Biovail’s claims. Part II analyzes Biovail’s claims with respect to potential violations by
Hoechst under section 1 and section 2 of the Sherman Antitrust
Act (the “Sherman Act”). Part III analyzes Hoechst’s immunity
under the Noerr Immunity doctrine. This Comment concludes that
the Noerr Immunity doctrine protects Hoechst, even if they intended to manipulate the Hatch-Waxman Act.
I. LEGAL FRAMEWORK
Biovail’s claims against Hoechst invoke issues of patent infringement and the Hatch-Waxman Act. This section reviews both
of these aspects, and presents Biovail’s claims.
A. Patent Infringement
Hoechst, like any patent owner, has the right to exclude others
from making, using or selling Cardizem in the United States during
the lifetime of its patent.8 Under current law, the lifetime of a
United States patent grant shall be “for a term beginning on the
date on which the patent was issued and ending twenty years from
the date on which the application for the patent was filed in the
United States.”9 Any competitor who sells a generic version of
Cardizem commits an act of patent infringement: an individual or
company that “without authority makes, uses, offers to sell, or sells
any patented invention, within the United States or imports into the
United States any patented invention during the term of the patent
therefor, infringes the patent.”10 An individual or corporation who
infringes a U.S. patent may be found liable to the patent owner for
treble damages.11
Manufacturers of generic pharmaceuticals, such as Biovail,
of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or
of the press; or the right of the people peaceably to assemble, and to petition the Government for a redress of grievances.” Id.
8. See 35 U.S.C. § 271(a) (Supp. III 1997); 35 U.S.C. § 283 (1994).
9. 35 U.S.C. § 154(a)(2) (1994). Special rules apply for patents if the application on
which it issues was filed prior to June 8, 1995. See 35 U.S.C. § 154(c)(1) (1994).
10. 35 U.S.C. § 271(a).
11. 35 U.S.C.§ 284 (1994).
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may seek FDA approval to sell patented drugs under the HatchWaxman Act, prior to the expiration of the U.S. patent.12 Seeking
approval from the FDA under the Hatch-Waxman Act for a patented drug, however, constitutes an act of patent infringement.13
B. FDA Approval of Patented Drugs Under the HatchWaxman Act
Under the Hatch-Waxman Act, the FDA approval process requires that the generic manufacturer file an Abbreviated New Drug
Application (“ANDA”).14 The ANDA allows a generic equivalent
of brand name drugs to forego expensive and lengthy clinical testing and rely on the test results of the brand name counterpart.15 In
addition, the process requires the generic manufacturer to state that
the patent for the drug is invalid or will not be infringed by the generic counterpart and to notify the holder of the patent that an
ANDA has been filed.16 Once notified, the patent holder may sue
the applicant for patent infringement on the basis of the ANDA.17
Since the cost and risk of patent litigation is high,18 HatchWaxman provides an incentive for generic manufacturers to challenge patents on drugs which may be invalid, unenforceable or not
infringed by the ANDA.19 The incentive is the right to a 180-day
exclusivity period for the first manufacturer to submit an ANDA
for a specific generic drug.20 The exclusivity period starts from the
12. 21 U.S.C. § 355(j) (1994 & Supp. IV 1998).
13. 35 U.S.C. § 271(e)(2) (1994).
14. 21 U.S.C. § 355(j)(2)(A)(vii) (1994).
15. Id.; See also Melissa K. Davis, Monopolistic Tendencies of Brand-Name Drug
Companies in Pharmaceutical Industry, 15 J.L.& COM. 357, 363-65 (1995). The policy
basis for Hatch-Waxman is to increase the number of generic drugs available to consumers by providing an accelerated mechanism whereby generic manufacturers can challenge
patented drugs. Hatch-Waxman also benefits companies that develop new drugs by extending the patent lifetime when approval for new drug results in a shortened marketing
period during which the drug enjoys patent protection. Id.
16. 21 U.S.C. § 355(j)(2)(A)(vii).
17. 35 U.S.C. § 271(e)(2). The filing of a patent suit based on an ANDA delays the
marketing of the generic drug by 30 months or until resolution by the parties, whichever
comes first. Id.
18. Damages paid by the infringing party may be up to three times the actual damages incurred by the plaintiff. 35 U.S.C. § 284 (1994).
19. 21 U.S.C. § 355(j)(5)(B)(iv) (Supp. IV 1998).
20. Id.

RESEKFMT.DOC

2000]

9/29/2006 3:19 PM

BIOVAIL v. HOECHST AKTIENGELLSCHAF

575

earlier of either: (i) the day that the initial applicant first markets
the drug (the “commercial marketing trigger”) or (ii) the day a
court decides the original patent is invalid or not infringed by the
generic drug (the “court decision trigger”).21 During the exclusivity period, the FDA will not approve any subsequent ANDAs.22
Consequently, the first company to file an ANDA can market its
drug without generic competition for 180-days, thus increasing the
likelihood that the first company will become the dominant generic
supplier when the exclusivity period expires.23
In Biovail, the first company to apply for an ANDA to sell generic Cardizem was the drug manufacturer Andrx.24 Andrx filed
an ANDA in September of 1995 and thereafter served on Hoechst
certification that the ANDA did not infringe any outstanding
Hoechst patents.25 Hoechst responded by filing a patent infringement action against Andrx.26 On September 15, 1997, the FDA
gave preliminary approval for Andrx to market the generic form of
Cardizem.27 On September 26, 1997, Hoechst and Andrx entered
into a partial settlement agreement.28 Under the partial settlement,
Hoechst and Andrx agreed to continue litigating the infringement
suit in the courts.29 However, Hoechst promised to make quarterly
payments to Andrx in the amount of ten million dollars.30 In exchange, Andrx agreed to refrain from marketing its generic drug
until the resolution of the suit and to assert its right of exclusivity,
as the first in line, against other potential producers of generic Cardizem.31 Since reaching the agreement, neither Hoechst nor Andrx
have actively advanced the litigation.32
21. Id.
22. 35 U.S.C. § 271(e)(2) (1994).
23. Id.
24. See Aetna U.S. Healthcare, Inc., v. Hoechst Aktiengesellschaf, Inc., 54 F. Supp.
2d 1042, 1046 (1999) (remanding to Kansas state court for lack of subject matter jurisdiction).
25. Id.
26. Id.
27. Id.
28. Id.
29. Id.
30. Id.
31. Id.
32. Id.
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On June 19, 1997, Biovail filed an ANDA with the FDA for
approval of a generic form of Cardizem.33 However, Biovail was
prevented from obtaining preliminary FDA approval for its generic
Cardizem because Andrx’s 180-day exclusivity period had not yet
been triggered and therefore had not expired.34 Consequently,
Biovail was locked out of the Cardizem market.
C. Biovail’s Claims
Biovail brought suit against Hoechst alleging that the partial
settlement agreement between Hoechst and Andrx violated the
Sherman Antitrust Act35 because it represented an illegal agreement between competitors to restrain trade and willfully maintain a
monopoly by Hoechst.36 Hoechst responded by seeking dismissal
of the claims, asserting that Biovail could not show a sufficient set
of facts to make a prima facie case that Hoechst violated the antitrust laws in any way that might entitle Biovail to relief.37 Thus,
the issue in the case was whether Biovail’s complaint should be
dismissed or whether the claims merited a trial.38
In a motion to dismiss, all of Biovail’s well-pleaded complaints
are accepted as true and all reasonable inferences are drawn in favor of Biovail.39 Hoechst’s motion to dismiss would be granted if
the court found “beyond doubt that . . .[plaintiff could] . . . prove
no set of facts in support of [its] claim which would entitle [it] to
relief”.40
Hoechst acknowledged that the partial settlement agreement
with Andrx included that (1) Hoechst would continue to prosecute
its patent infringement claims against Andrx; (2) Andrx would
withdraw its counterclaims against Hoechst; (3) Hoescht would
make quarterly payments in the amount of ten million dollars to
Andrx; (4) Andrx agreed to refrain from marketing generic Cardizem until the resolution of the suit; (5) Andrx would continue to
33.
34.
35.
36.
37.
38.
39.
40.

See Biovail, 49 F. Supp. 2d at 757.
See id. at 758.
15 U.S.C. §§ 1, 2 (1994).
Biovail, 49 F. Supp. 2d at 758.
Id.
FED. R. CIV. P. 12(B)(6).
Cruz v. Beto, 405 U.S. 319, 323 (1972).
Conley v. Gibson, 355 U.S. 41, 45-46 (1957).
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prosecute its claim for FDA approval; and (6) Andrx would assert
its right as first in line to bar others from gaining FDA approval
and thereby entering the Cardizem market.41 Hoechst also did not
dispute that at the time of their motion to dismiss that they sold
80% of the Cardizem in the United States.42
II. ANALYSIS OF BIOVAIL’S CLAIMS UNDER THE SHERMAN
ANTITRUST ACT
Whether Biovail’s claims were sufficient to maintain an action
against Hoechst was decided under the Sherman Act43, which protects consumers from high prices and reduced output caused by
cartels and monopolies.44 Biovail’s claims were properly brought
under the Sherman Act because the claims alleged that the
Hoechst-Andrx suit and partial settlement unfairly blocked Biovail
from selling an inexpensive, generic version of Cardizem, and that
Hoechst thereby illegally restrained interstate trade and maintained
an illegal monopoly on Cardizem.
In this section the antitrust elements of Biovail’s claims are
analyzed and the decision of the district court is presented.
A. Section 1 of the Sherman Antitrust Act
In order to establish a violation of section 1 of Sherman Act,45
Biovail must establish that Hoechst engaged in (1) a conspiracy (2)
to unreasonably restrain trade.46 A conspiracy “must comprise an
41. Biovail, 49 F. Supp at 761; Aetna U.S. Healthcare, Inc., v. Hoechst Aktiengesellschaf, Inc., 54 F. Supp. 2d 1042, 1046 (1999).
42. Biovail, 49 F. Supp at 761.
43. 15 U.S.C. §§ 1, 2 (1994).
44. HERBERT HOVENKAMP, FEDERAL ANTITRUST POLICY THE LAW OF COMPETITION
AND ITS PRACTICE, 50 (1994).
45. 15 U.S.C. § 1. Section 1 states “every contract, combination in the form of trust
or otherwise, or conspiracy, in restraint of trade or commerce among the several States,
or with foreign nations, is hereby declared to be illegal.” Id.
46. Id.; Summit Health, Ltd v. Pihas, 500 U.S. 322, 330 (1991) (holding that an interstate nexus must be shown to establish Federal jurisdiction.) The plaintiff or the
prosecution must allege and prove that the defendant’s illegal activities had a substantial
impact under the commerce clause. This requires a showing that the defendants act is
itself in interstate commerce or that it has an effect on interstate commerce. In Summit
Health the Court held that a boycott designed to deny hospital staff privileges to a surgeon was reachable under the Sherman Act because the hospital itself was within the
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agreement or meeting of the minds between at least two competitors, for the purpose or with the effect of unreasonably restraining
trade”.47 The making of the illegal agreement itself is the violation.48 Completing the conspiracy, an act furthering the conspiracy, or the success of the conspiracy do not have to be shown because they are not elements of the offense.49 Parties are liable so
long as they made an illegal agreement.50
An unreasonable “‘restraint of trade’ . . . [refers to] . . . a particular economic consequence, which may be produced by quite
different sorts of agreements . . . .”51 Economic consequences may
include eliminating competition, creating a monopoly, price fixing
or interfering with free market forces.52
The courts have developed three methods of analyzing agreements to determine whether they constitute conspiracies to unreasonably restrain trade. The first analysis concerns agreements,
which are illegal “per se.”53 An agreement is illegal per se when
the restraint of trade has no legitimate justification, lacks any redeeming competitive purpose and “would always or almost always
tend to restrict competition and decrease output.”54 Examples of
per se violations include price fixing, allocations of markets and

reach of congress and both the hospital and the plaintiff regularly served out-of state patients. In Biovail, the parties did not dispute the effect on interstate commerce. See Biovail, 49 F. Supp. 761 n. 4.
47. Meredith E.B. Bell & Elena Laskin, Antitrust Violations, 36 AM. CRIM. L. REV.
357, 359 (1999) citing 15 U.S.C. § 1 (1994).
48. United States v. Socony-Vacuum Oil Co., 310 U.S. 150, 223-24 n.59 (1940)
(holding that an agreement to reduce output by independent members of a cartel violated
Section I of the Sherman Antitrust Act, even though the agreement did not directly fix
prices).
49. Socony-Vacuum, 310 U.S. at 223-24 n. 59.
50. Id.
51. Business Elec. Corp. v. Sharp Elec. Corp., 485 U.S. 717, 731 (1988).
52. See Bell, supra note 47, at 360.
53. Id.
54. Broadcast Music v. Columbia Broad. Sys., 441 U.S. 1; 19-20 (1979). (holding
that a blanket license arrangement which literally involved price fixing was not a per se
violation of the Sherman Act because the arrangement so significantly reduced transaction costs that it effectively made mass marketing of performance rights feasible); See
also United States v. Topco Ass’n,, 405 U.S. 596 (1972) (holding that the allocations of
markets was a per se violation of Section 1 of the Sherman Antitrust Act).
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group boycotts.55 When an alleged agreement is illegal per se, no
facts need to be proven beyond the making of the agreement.56
The second analysis is the “Rule of Reason”.57
Rule of Reason analysis focuses on the state of competition
with, as compared to without, the relevant agreement. The central
question is whether the relevant agreement likely harms competition by increasing the ability or incentive profitably to raise price
above or reduce output, quality, service, or innovation below what
likely would prevail in the absence of the relevant agreement.58
The Rule of Reason analysis allows courts to factor in the defendant’s assertion that an allegedly anti-competitive agreement
may increase economic efficiency and competitiveness, and therefore not constitute a violation of the Sherman Act.59 The nature of
the agreement and the absence of market power to control output
or fix prices may actually demonstrate the absence of anticompetitive harm.60
The third analysis is the quick look doctrine.61 The quick look
doctrine combines per se analysis with the more in depth inquiry of
the Rule of Reason.62 The quick look doctrine is used to determine
the legality of agreements that are not inherently competitive.63
Under the quick look doctrine, the court is allowed to consider
procompetitive justification for an agreement asserted by the defendant.64 If the defendant successfully presents a procompetitive
justification, then the court must do a complete examination under
the Rule of Reason.65,
55. See Bell, supra note 47, at 360, n.45.
56. Socony-Vacuum, 310 U.S. at 223-224 n. 59.
57. National Soc’y of Prof’l. Eng’rs. v. United States, 435 U.S. 679, 692 (1978)
(holding that under Rule of Reason, the defendant must show that a particular practice is
not anticompetitive.)
58. Antitrust Guidelines for Collaborations Among Competitors, (visited Apr. 28,
2000) <http://www.ftc.gov/os/1999/9910/jointventureguidlines.htm> [hereinafter, Antitrust Guidelines]
59. Professional Eng’rs, 435 U.S. at 687-89.
60. See Antitrust Guidelines, supra note 58.
61. See Bell, supra note 47, at 360.
62. Broadcast Music v. Columbia Broad. Sys., 441 U.S. 1; 17, n. 27 (1979).
63. See Bell, supra note 47, at 360.
64. Id.
65. Broadcast Music, 441 U.S. at 20-25.
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B. Section 2 of the Sherman Antitrust Act
Biovail also alleged that Hoechst violated section 2 of the
Sherman Act66 by monopolizing or attempting to monopolize the
market for Cardizem.67 section 2 prohibits monopolization, attempts to monopolize and conspiracies to monopolize.68 Monopolization is shown by “(1) the possession of monopoly power in the
relevant market and (2) the willful acquisition or maintenance of
that power as distinguished from growth or development as a consequence of a superior product, business acumen, or historic accident.”69 Attempted monopolization differs from actual monopolization by requiring a showing of anticompetitive or predatory
behavior, a dangerous probability of successful monopolization,
and a specific intent to monopolize.70
In order to determine whether a firm has committed illegal monopolization, it is first necessary to define a relevant market.71 The
relevant market is defined according to the product at issue and
66. 15 U.S.C. § 2 (1994). Section 2 states, “Every person who shall monopolize, or
attempt to monopolize, or combine or conspire with any other person or persons to monopolize . . . shall be deemed guilty of a felony . . . .” Id.; Unlike section 1, section 2 may
apply to the conduct of single entities. See United States v. Griffith et al., 334 U.S. 100,
107 (1948). As stated by Mr. Justice Douglas for the Court majority:
A man with a monopoly of theatres in any one town commands the entrance for
all films into that area. If he uses that strategic position to acquire exclusive
privileges in a city where he has competitors, he is employing his monopoly
power as a trade weapon against his competitors. It may be a feeble, ineffective
weapon where he has only one closed or monopoly town. But as those towns
increase in number throughout a region, his monopoly power in them may be
used with crushing effect on competitors in other places.
Id.
Conspiracy to monopolize was not alleged in Biovail and will not be considered. See Biovail, 49 F. Supp. at 761.
67. Biovail, 49 F. Supp. at 761.
68. 15 U.S.C. § 2.
69. United States v. Grinell Corp., 384 U.S. 563, 570-571 (1966) (holding that section 2 of the Sherman Act was violated by a high percentage of the market which was
obtained in large part by unlawful and exclusionary practices).
70. Spectrum Sports, Inc., v. McQuillan, 506 U.S. 447, 456 (1993) (holding that
attempted monopolization may be proved where a defendant has engaged in predatory or
anticompetitive conduct with specific intent to monopolize and that there is a dangerous
probability that the defendant will achieve monopoly power); See also HOVENKAMP, supra note 44, at 248-49.
71. See HOVENKAMP, supra note 44, at 82-83.
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geography.72 The product market is defined according to the ability of consumers to find substitutes for the product.73 The geographic market can be defined locally, regionally or nationally by
considering whether consumers are able to travel to other districts
to obtain the goods at issue. 74
Having defined the relevant market, a court will ordinarily
compute the defendant’s percentage of output in the relevant market.75 The existence of monopoly power “ordinarily may be inferred from the predominant share of the market.”76 However,
monopoly power may also be defined as a large amount of market
power in a relevant market77 where market power is the “ability of
a firm to increase its profits by reducing output and charging more
than a competitive price for its product”.78
Thus, monopolization is likely to be found if there are no product substitutes in the relevant market and a firm may raise prices or
reduce output without causing customers to seek substitute products in such numbers that a price increase would be unprofitable.79,
C. Patent Misuse
Significantly, Biovail did not argue that Hoechst violated section 2 of the Sherman Act by abusing patent rights. Courts do not
presume that the patent holder’s right to exclude establishes market
power in an antitrust sense.80 As described by the Federal Circuit,
“[t]he virtually unlimited variety and scope of patented inventions
and market situations militate against per se rules in these situations.”81 Moreover, the patent holder’s right to exclude competi-

72. Id.
73. Grinell, 384 U.S. at 571.
74. Id. (holding that the market at issue was nationwide rather then local. In a patent case the geographic market is defined nationally.)
75. See HOVENKAMP, supra note 44, at 82.
76. Grinnell, 384 U.S. at 571.
77. See HOVENKAMP, supra note 44, at 243.
78. Id. at 79.
79. See id. at 242
80. Abbot Labs. v. Brennan, 952 F. 2d 1346, 1354 (Fed. Cir. 1991) (holding that
existence of patent does not of itself establish presumption of market power in antitrust
sense).
81. C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1368 (Fed. Cir. 1998).
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tors by itself does not constitute monopoly power forbidden by the
section 2.82 Antitrust laws do not require a “patent holder to forfeit
the exclusionary power inherent in his patent the instant his patent
monopoly affords him monopoly power over a relevant market.”83
However, a firm that engages in patent misuse will be liable
under section 2.84 Patent misuse occurs when a patent is being
used anticompetitively and outside the scope of the patent grant.85
The patent misuse doctrine is typically invoked as a defense when
a patent owner sues a defendant for patent infringement.86 For example, in Walker Process the Supreme Court found patent misuse
occurred when a patent owner sued a defendant for infringement
on a patent that the patent owner knew was obtained through
fraud.87
D. Analysis of Biovail’s Claims Under the Sherman Act
Biovail claimed essentially that Hoechst subverted the FDA
regulatory scheme for anticompetitive purposes.88 Biovail argued
that under a Rule of Reason analysis, the Hoechst-Andrx partial
settlement violated section 1 because it harmed competition and
restrained trade.89 The partial settlement was an agreement between the competitors, Hoechst and Andrx, which kept Biovail out
of a market that Biovail would be allowed to enter in the absence
of the agreement.90 Biovail argued, the ongoing infringement ac82. Walker Process Equip., Inc. v. Food Mach. & Chem. Corp., 382 U.S. 172, 17778 (1965) (holding that obtaining a patent by fraud was a violation of Section 2 of the
Sherman Antitrust Act).
83. SCM Corp. v. Xerox, 645 F.2d 1195, 1204 (2d Cir. 1981) (holding that the accumulation of all patents in a market area, thus making it much more difficult for other
firms to compete, does not violate antitrust laws).
84. See Barry Evans, Boundaries have Changed for Patent Misuse Defense, Despite
Limitations Reports of Its Death Exaggerated, N.Y.L.J., February 17, 1998, at S6, col. 3.
85. See HOVENKAMP, supra note 44, at 218.
86. See id.
87. Walker Process Equip., Inc. v. Food Mach. & Chem. Corp., 382 U.S. 172
(1965).
88. See Woods Exploration & Producing Co. v. Aluminum Co. of Am., 438 F.2d
1286, 1303 (5th Cir. 1971), cert denied, 404 U.S. 1047 (1972) (holding that policies of
the Sherman Act should not be sacrificed simply because defendants employ governmental processes to accomplish anticompetitive purposes).
89. Biovail, 49 F. Supp. 759-760.
90. Id.
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tion and partial settlement was evidence of an agreement which
violated section 1. Hoechst, by engaging in tactics to forestall
marketing generic Cardizem, reduced competition in Cardizem
and, consequently, was able to charge elevated prices and reap illegal profits.91
Biovail’s claims under section 2 of the Sherman Act asserted
that Hoechst had achieved monopoly power in the relevant market
for Cardizem because Hoechst sold 80 % of the Cardizem in the
United States and, therefore, monopolization could be inferred
from its predominant share of the market.92 Biovail further alleged
that Hoechst violated section 2 by willfully seeking to maintain its
monopoly power. Biovail claimed that Hoechst, having the intent
to monopolize, engaged in anticompetitive conduct because by using the ongoing infringement suit and partial settlement agreement
to block all sales by later ANDA applicants. Thus, Hoechst’s actions maintained a monopoly for Hoechst.
Hoechst responded that Biovail’s injury was speculative.93
First, Hoechst argued that Biovail’s claims were not ripe because
Biovail had not yet been granted tentative approval by the FDA for
its generic Cardizem.94 Therefore, Biovail could not show that it
was being kept out of a market to which it was otherwise entitled.
Second, Hoechst argued Biovail could not show that the HoechstAndrx agreement unreasonably restrained trade. Regardless of the
partial settlement, Andrx may have decided not to start marketing
Cardizem, until the conclusion of the Hoechst-Andrx patent infringement trial.95 Hoechst noted that should Andrx go forward
with marketing before the conclusion of the infringement suit,
Andrx might be subject to triple damages for willful patent infringement in the event that Andrx lost the suit. Hoechst argued
that even the FDA recognized that “a prudent ANDA applicant”
may wish to delay marketing to avoid the risk of potentially devastating damages.96 Third, Hoechst responded that Biovail’s claim
91.
92.
93.
94.
95.
96.

Id.
Id. at 766, relying on United States v. Grinell Corp., 384 U.S. 563, 571 (1966).
Id.
Id.
Id.
Id.
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consisted of nothing more then frustration with the Hatch-Waxman
exclusivity period.97
E. The Decision of the District Court
While the court admitted that Hoechst’s arguments were significant, it did not dismiss the case. The court reasoned that
while it is possible that Andrx is not marketing its generic
product because it does not want to risk potential patent infringement damages, it is certainly possible that Andrx is
not marketing its generic product-and hence stalling the exclusivity period because the defendant is paying it forty
million dollars.98
Since Hoechst could not show the absence of a prima facie, the
case was not dismissed.99
III. HOECHST ENJOYS IMMUNITY FOR ALLEGED VIOLATIONS OF THE
SHERMAN ANTITRUST ACT UNDER THE NOERR-PENNINGTON
DOCTRINE
Even if Biovail succeeds in making a prima facie case under
the Sherman Act, it is likely that Hoechst will enjoy substantial
Noerr Immunity for the partial settlement and the Hoechst-Andrx
lawsuit.100 Noerr Immunity limits the antitrust laws by insuring
that private activities aimed at influencing the government are immune from prosecution, even though such activities may restrain
trade or result in a monopoly.101 The policy behind Noerr is that if
the antitrust laws were not so limited then, the antitrust laws would
violate the right to petition the government as guaranteed under the
First Amendment of the Constitution.102 Thus, Noerr Immunity
97. Id.
98. Id.
99. Id. at 777.
100. See Parker v. Brown, 317 U.S. 341 (1943) (stating that the Noerr doctrine is
based on the presumption that the government cannot violate the antitrust laws). See also
Eastern R.R Conference v. Noerr Motor Freight, Inc, 365 U.S. 127, 145 (1961) (holding
that a restraint upon trade or monopolization resulting from a valid governmental action
can result in a violation of the Sherman Act).
101. Eastern R.R , 365 U.S. at 145.
102. California Motor Transp. Co. v. Trucking Unlimited, 404 U.S. 508 (1972)

RESEKFMT.DOC

2000]

9/29/2006 3:19 PM

BIOVAIL v. HOECHST AKTIENGELLSCHAF

585

necessarily balances the Sherman Act’s interest in promoting competition against the constitutionally guaranteed right to petition the
government for a redress of grievances.
A. The Noerr-Pennington Doctrine
The Noerr Immunity doctrine was originally articulated in
Eastern Railroad Conference v. Noerr Motor Freight, Inc.103 In
Eastern Railroad, the issue was whether the defendant’s railroads
violated sections 1 and 2 of the Sherman Act by conducting a publicity campaign urging the passage of state laws that would harm
the trucking industry.104 The Court held that even though the railroads may have used unethical business practices to destroy the
truckers as competitors, the Sherman Act was not applicable because the activities at issue were limited to soliciting the Legislature and the Executive to pass and enforce specific laws.105 The
Court held:
[i]n a representative democracy such as this, these branches
of government act on behalf of the people and, to a very
large extent, the whole concept of representation depends
upon the ability of the people to make their wishes known
to their representatives. To hold that the government retains
the power to act in this representative capacity and yet
hold, at the same time, that the people cannot freely inform
the government of their wishes would impute to the
Sherman Act a purpose to regulate, not business activity,
but political activity, a purpose which would have no basis
whatever in the legislative history of that Act. Secondly,
and of at least equal significance, such a construction of the
Sherman Act would raise important constitutional ques(holding that it would be destructive of rights of association and of petition to hold that
groups with common interests may not, without violating antitrust laws, use channels and
procedures of state and federal agencies and courts to advocate their causes and points of
view respecting resolution of their business and economic interests vis-a-vis their competitors); James B. Perrine, Defining the Sham Limitation to the Noerr-Pennington Antitrust Immunity Doctrine: An Analysis of the Professional Real Estate Investors v. Columbia Pictures Industries Decision 46 ALA. L. REV. 815 (1995).
103. 365 U.S. 127, 145 (1961).
104. Id.
105. Id.
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tions. The right of petition is one of the freedoms protected
by the Bill of Rights, and we cannot, of course, lightly impute to Congress an intent to invade these freedoms.106
In California Motor Transportation Co. v. Trucking Unlimited,
the Court definitively extended Noerr Immunity to also protect the
right to petition administrative agencies and the courts. 107 In California Motor, it was alleged that the antitrust defendants engaged
in a concerted effort to bring actions against the plaintiffs before
state and federal agencies in order to destroy the plaintiffs as competitors.108 It was further alleged that the defendants brought these
actions irrespective of the merits and with the sole purpose of destroying the competitive ability of the plaintiffs.109 The Court held
that Noerr Immunity allowed the defendants to have the right to
access courts and agencies to defeat the applications of competitors
because the Sherman Act could not be construed to limit access to
agencies or the courts.110 The Court stated:
[t]he same philosophy governs the approach of citizens or
groups of them to administrative agencies (which are both
creatures of the legislature, and arms of the executive) and
to courts, the third branch of Government. Certainly the
right to extends to all departments of the Government. The
right of access to the courts is indeed but one aspect of the
right of petition. We conclude that it would be destructive
of rights of association and of petition to hold that groups
with common interests may not, without violating the antitrust laws, use the channels and procedures of state and
federal agencies and courts to advocate their causes and
points of view respecting resolution of their business and
economic interests vis-à-vis their competitors.111

106.
107.
108.
109.
110.
111.

Id. at 137-38.
404 U.S. 508 (1972).
Id.
Id.
Id. at 519.
Id. (citation omitted).
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B. The Sham Exception to Noerr-Pennington
However, in California Motor, the Court recognized that immunity under the Noerr Immunity doctrine was limited.112 The
Court held that Noerr Immunity did not apply to litigation which
“is a mere sham to cover what is actually nothing more than an attempt to interfere directly with the business relationships of a competitor . . . . [In that case] . . . the application of the Sherman Act
would be justified.”113
The Court did not specify the types of activities that constitute
a sham lawsuit. As they observed, “[o]pponents before agencies or
courts often think poorly of the other’s tactics, motions or defenses
and may readily call them baseless.”114 The majority opinion,
written by Justice Douglas, suggested that sham litigation was apparent when there was “a pattern of baseless, repetitive claims . . .
which leads the factfinder to conclude that the administrative and
judicial process have been abused.”115
Justice Stewart’s concurring opinion in California Motor was
that sham litigation analysis required a subjective inquiry that accounted for the intent of the accused.116 The plaintiffs “are entitled
to prove that the real intent of the conspirators was not to invoke
the processes of the administrative agencies and courts but to discourage and ultimately to prevent the respondents from invoking
those processes.”117 Upon the showing of intent, “the application
of the Sherman Act would be justified”.118
This disagreement between Justice Douglas and Justice Stewart, whether analysis of sham litigation should be determined using
an objective or intent based test, represented a dispute which continued in the Court for several years. In the words of one commentator, “[t]he Court’s uncertainty concerning what constitutes a
sham has been remarkable. In almost every Noerr case since Pennington in 1965 the court has rephrased its standard for determin112.
113.
114.
115.
116.
117.
118.

Id. at 511.
Id. (quoting Eastern R.R., 365 U.S. at 144.)
Id. at 513.
Id.
Id. at 516.
Id. at 518.
Id.(quoting Eastern R.R., 365 U.S. at 144).
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ing whether antitrust conduct would be viewed as a sham.”119
In Professional Real Estate Investors v. Columbia Pictures
(“PRE”), the Supreme Court finally held that the sham inquiry
contained an indispensable objective, as well as a subjective component.120 Justice Thomas, writing for the majority, outlined a
two-part test under which an antitrust plaintiff must first show that
a lawsuit is objectively baseless and then show that the lawsuit was
initiated with bad faith to destroy the plaintiff as a competitor:
First, the lawsuit must be objectively baseless in the sense that
no reasonable litigant could realistically expect success on the merits. If an objective litigant could conclude that the suit is reasonably calculated to elicit a favorable outcome, the suit is immunized
under Noerr, and an antitrust claim premised on the sham exception must fail. Only if a challenged litigation is objectively meritless may a court examine the litigant’s subjective motivation. Under the second part of our definition of a sham, the court should
focus on whether the baseless litigation conceals an attempt to interfere directly with the business relationships of a competitor.121
The court compared the objectively baseless standard for sham
litigation to bringing a wrongful civil proceeding.122 The Court
reasoned by analogy that for the defendant to not have Noerr Immunity, the antitrust plaintiff must demonstrate that there was absolutely no objective merit to the defendant’s position because the
claims were so baseless that no reasonable litigant could realistically expect to secure favorable relief.123 Since in a wrongful civil
proceeding “the absence of probable cause is an essential element
of the suit,” the defendant could defeat an allegation of sham litigation by showing probable cause.124 Moreover, the court held, as in
a wrongful civil proceeding action, “[p]robable cause to institute
civil proceeding requires no more than a reasonable belief that
119. Perrine, supra note 102, at 825, n. 61.
120. Professional Real Estate Investors v. Columbia Pictures, 508 U.S. 49 (1993)
(holding that an objectively reasonable effort to litigate cannot be “sham,” within meaning of exception to Noerr doctrine immunity from antitrust liability, regardless of plaintiff’s subjective intent).
121. Id. at 60-61.
122. Id. at 58.
123. Id. at 62.
124. Id. at 63.
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there is a chance that [a] claim may be held valid upon adjudication.”125
Although Justice Stevens concurred with the results of the decision in PRE, he sharply disagreed with the objectively baseless
standard advanced by the Court.126 He argued that the objectively
baseless standard for determining whether a lawsuit was a sham
was too broad because the standard would encompass lawsuits that
reasonable litigants could expect to win, but which were nevertheless a sham designed to keep competitors out of a market.127 Stevens believed sham litigation was “appropriately applied to a case,
or series of cases, in which the plaintiff is indifferent to the outcome of the litigation itself, but has nevertheless sought to impose
a collateral harm on the defendant”.128
The different standards articulated by the majority and concurring opinions in PRE reflected the different policy concerns.
Thomas was concerned that a subjective test would undermine Noerr Immunity.129 Thus, he believed that an objectively baseless
standard would give “real intelligible guidance” as when to apply
the sham exception.130 Stevens, on the other hand, was concerned
that the objectively baseless standard would allow monopolists to
bring actions, which had “a colorable basis in law” but, were nonetheless designed to harass potential competitors. 131 Thus, Stevens
thought that the objective standard would allow potential antitrust
defendants to escape liability. He advanced a standard, which allowed for the analysis of sham litigation on a case by case basis.132
125. Id. (quoting Hubbard v. Beatty & Hyde, Inc., 343 Mass. 258, 262 (1961)).
126. Professional Real Estate, 508 U.S. at 67.
127. Id.
128. Id. at 68 (Stevens, J., concurring).
129. Id. at 60.
130. Id. (quoting Allied Tube & Conduit Corp. v. Indian Head, Inc., 486 U.S. 492,
503 (1988)).
131. Id. at 73 (Stevens concurrence quoting Grip-Pak, Inc. v. Illinois Tool Works,
Inc., 694 F.2d 466, 472 (1982)).
132. Stevens stated:
[i]n sum, in this case I agree with the Court’s explanation of why respondents’
copyright infringement action was not “objectively baseless,” and why allegations of improper subjective motivation do not make such a lawsuit a “sham.” I
would not, however, use this easy case as a vehicle for announcing a rule that
may govern the decision of difficult cases, some of which may involve abuse of
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C. Noerr-Immunity Protects Hoechst from Liability
Noerr Immunity protects Hoechst from liability for Biovail’s
antitrust injuries arising out of the Hoechst-Andrx suit and the partial settlement. Since Noerr immunizes Hoechst’s right to petition
the government for grievances, Hoechst is protected from liability
for the Hoechst-Andrx lawsuit. Hoechst cannot incur antitrust liability for bringing suit against Andrx because to do so would deny
Hoechst access to the courts.
Noerr also immunizes the Hoechst-Andrx partial settlement
because the partial settlement agreement is a private action which
is incidental to a valid effort to influence government action. As
explained in Allied Tube, “where, independent of any government
action, the anticompetitive restraint results directly from private
action, the restraint cannot form the basis for antitrust liability if it
is “incidental” to a valid effort to influence governmental action.”133 Thus, Andrx’s agreement with Hoechst not to sell Cardizem, thereby preventing the exclusivity period from being triggered is protected under Noerr.
Moreover, Hoescht is operating within the scope of their patent
rights by limiting Andrx’s production of a patented drug. Since the
Cardizem patents are presumed valid for the duration of the
Hoechst-Andrx lawsuit, Hoechst has the right to prevent Andrx
from making and selling Cardizem for the duration of the trial. 134
If necessary, Hoechst could obtain a preliminary injunction to prevent Andrx from selling Cardizem for the duration of the lawsuit.
135
Any law that prevented Hoechst from limiting Andrx’s production and sale of Cardizem during the trial would effectively limit
Hoechst’s access to the courts to enforce their patent, violating
the judicial process. Accordingly, I concur in the Court’s judgment but not in
its opinion.
Id. at 75.
133. Allied Tube, 486 U.S. at 499.
134. C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1369 (Fed. Cir. 1998) (holding that clear and convincing affirmative evidence is required to show that the presumption of validity is not justified and that the patent is being misused to create an antitrust
violation).
135. The purpose of a preliminary injunction is to preserve the status quo pending
either a permanent injunction or a trial on the merits. FED. R. CIV. P. 65 (A) (1); See
O’CONNOR’S FEDERAL RULES, Chapter 2, § 3, 63 (1998).
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Hoechst’s First amendment right to petition the government for
grievances.136
Noerr also immunizes Andrx’s agreement to assert its rights as
the first ANDA applicant because Andrx is merely exercising its
rights before the FDA. If Andrx could not petition the FDA to
block later ANDA applicants, then Andrx’s right to petition the
government for grievances would be blocked.
Hoechst cannot be liable for Biovail’s inability to enter the
Cardizem market because the antitrust harm to Biovail is the result
of the exclusion period of the Hatch-Waxman Act in combination
with the patent laws, rather then a direct action of Hoechst or
Andrx. Hoechst is merely pursuing its own interest under HatchWaxman. As the Supreme Court stated in City of Columbia v.
Omni Outdoor Advertising:137
Any lobbyist or applicant, in addition to getting himself
heard, seeks by procedural and other means to get his opponent ignored. Policing the legitimate boundaries of such
defensive strategies, when they are conducted in the context of a genuine attempt to influence governmental action,
is not the role of the Sherman Act.138
Preventing Hoechst from pursuing their interests under HatchWaxman cannot be accomplished without limiting Hoechst’s First
Amendment right to petition the government. Thus, even though
Hoechst’s activities may have been part of a strategy to dominate
the Cardizem market, they are immune under Noerr for antitrust
injuries to Biovail.
D. The Hoechst Suit Against Andrx is not a Sham
Biovail would probably respond to Hoechst’s claim for immunity under the Noerr Immunity doctrine by arguing that the
Hoechst-Andrx dispute was an example of sham litigation, intended to keep Biovail from entering the Cardizem market. However, under the objectively baseless standard articulated in PRE,

136. U.S. CONST. amend. I.
137. 499 U.S. 365, 367 (1990).
138. Id. at 382.
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Biovail probably will not prevail.
The objectively baseless standard allows an antitrust defendant
to irrefutably defeat a claim of sham litigation by showing that
they had probable cause to sue. Probable cause “requires no more
than a reasonable belief that there is a chance that [a] claim may be
held valid upon adjudication.” Hoechst will be able to show as a
matter of law that they had probable cause to sue Andrx for patent
infringement.
To appreciate the reason that Hoechst can show probable cause
as a matter of law, it is useful to compare Hoechst’s claims to those
of the plaintiff in PRE. In PRE, a motion picture studio, brought a
copyright infringement suit against the operators of a hotel. The
studio alleged that the defendant had infringed the plaintiff’s copyrights in various films by renting videocassettes to guests for viewing in hotel rooms.139 The Court reasoned probable cause could be
decided as a matter of law because there was no dispute as to the
facts underlying the legal claims.140
The Court noted that the studio’s copyright gave them the exclusive rights to perform the motion pictures publicly.141 The studio’s had this right regardless of whether “it intended any monopolistic or predatory use . . .”.142 “Indeed, to condition a
copyright upon a demonstrated lack of anticompetitive intent
would upset the notion of copyright as a ‘limited grant’ of ‘monopoly privileges’ intended simultaneously ‘to motivate the creative activity of authors’ and ‘to give the public appropriate access
to their work product.’”143 The Court concluded that since a reasonable copyright owner in the studio’s position would believe that
it had some chance of winning an infringement suit against the defendant, the studio could show probable cause to sue the hotel
owners. Having shown probable cause, the studio had defeated
any claim by the hotel operators that the studio’s lawsuit was a
sham.

139.
140.
141.
142.
143.

Professional Real Estate Investors v. Columbia Pictures, 508 U.S. 49 (1993).
Id. at 62.
Id. at 64; 17 U.S.C. § 106 (4) (Supp. IV 1998).
Professional Real Estate Investors, 508 U.S. at 64.
Id.
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As in PRE, the underlying facts of the Hoechst-Andrx patent
infringement suit are not in dispute. Hoechst owns a valid patent
in Cardizem. Andrx’s ANDA filing gave Hoechst a cause of action
to sue for patent infringement. Moreover, in the case of a patent
infringement suit, a court will presume that the infringement suit
was brought in good faith and was reasonable.144 Therefore,
Hoechst can show probable cause as a matter of law because any
reasonable patent owner in their position would believe that it had
some chance of winning an infringement suit against Andrx. Thus,
Biovail will not be able to show that the Hoechst-Andrx lawsuit
was objectively baseless.
Since under PRE, a plaintiff’s intent with regard to allegations
of sham litigation are only considered after a suit has been shown
to be objectively baseless, a court will not be able to consider evidence on whether Hoechst intentionally created an anticompetitive
situation by partially settling their suit with Andrx. However, even
if Biovail could show an objectively baseless lawsuit they probably
would not be able to show that Hoechst had the intent required for
sham litigation. Under PRE, the intent required is that the plaintiff
initiates the litigation to directly interfere with the defendant’s
business. Hoechst’s intent was to stop Andrx from infringing their
patent. Hoechst’s intent was not directed at Biovail. Since Biovail
could not show Hoechst initiated the litigation to interfere directly
with Biovail’s business, they can not show Hoechst had the required intent under PRE for sham litigation. As the Supreme Court
has stated, “the purpose of delaying a competitor’s entry into the
market does not render lobbying activity a ‘sham’ unless . . . the
delay is sought to be achieved only by the lobbying process itself,
and not by the governmental action that the lobbying seeks”. 145
It is interesting to speculate if the analysis presented by Justice
Stevens in PRE might result in a different outcome for Biovail’s
claims. Stevens argued that the objectively baseless standard was
too high because defendants who could establish probable cause,
might nevertheless be engaged in sham litigation. He proposed to
analyze whether litigation was a sham by determining if the liti-

144. C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1369 (Fed. Cir. 1998).
145. City of Columbia v. Omni Outdoor Advertising, 499 U.S. 365, 367 (1990).
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gants were indifferent to the outcome of the suit. Under the Steven’s analysis, Biovail could argue the Hoechst-Andrx litigation
was a sham because Hoechst was indifferent to the outcome of the
patent infringement suit. Hoechst indifference was evident because after reaching a partial settlement neither Hoechst nor Andrx
had advanced the litigation. Biovail could further assert that
Hoechst was simply prolonging the litigation as a strategy to delay
competitors from entering the Cardizem market. Thus, it is likely
that under Stevens analysis, Hoechst would be liable for antitrust
violations because their litigation qualified as a sham.
However, since the standard for determining whether a litigation is a sham is the objectively baseless standard articulated by the
Supreme Court in PRE, Biovail would not prevail by arguing that
the Hoechst-Andrx lawsuit is a sham.
CONCLUSION
Biovail v. Hoechst Aktiengesellschaft illustrates how the antitrust laws and Noerr Immunity are balanced between promoting
competition and protecting the right to petition the government
guaranteed by the Constitution. The Sherman Act prevents companies from illegally restraining trade or monopolizing markets.
Noerr Immunity limits the Sherman Act from infringing on the
right to petition when a party seeks to gain economic advantage
through the political or judicial system. The Supreme Court has
decided that the constitutional rights are sufficiently precious that
the standard to defeat Noerr Immunity using the sham exception is
very high.
In the present case, Noerr Immunity protects Hoechst from liability under the Sherman Act, even though Hoechst may have had
the intent to manipulate the Hatch-Waxman Act to keep competitors out of the Cardizem market. The Noerr Immunity doctrine is
justified because the alternative would be that the antitrust laws
would regulate Hoechst’s access to the courts, thereby jeopardizing
rights protected under the First Amendment of the constitution.

